# OnCo record nct03315026 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03315026/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03315026", "NCT03315026" ;
  schema:name "Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis"@en ;
  schema:description "A phase 2 trial of Siltuximab in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03315026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03315026> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:drugs <https://onco.cc/drugs/siltuximab/> .